Healthcare Startup Laboratoy work visual

Portfolio

A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

ABBA Therapeutics AG
ABBA Therapeutics develops therapeutic antibodies against novel targets for cancer immunotherapy.

β-catenin project
The beta catenin project aims to develop novel therapeutics for the treatment of colorectal, lung, liver, breast, brain and ovarian cancers by removing pathological proteins from the human body.

Anaveon
Anaveon is a late pre-clinical phase biotech based in Basel, Switzerland.  It focuses on the development of next generation IL-2 based therapeutic antibodies for tumor immunotherapy in melanoma, kidney carcinoma and lung cancer.

Avicenna Oncology
Avicenna Oncology GmbH is a biotechnology start-up, created in 2014 in Basel, Switzerland. Our lead program consists of ImmunoPayloads (ImPs), First In Class immuno-oncology therapeutics with a unique and innovating mode of action.

Biotech in stealth mode
Developing novel cell engineering-based treatments.

Biotech in stealth mode
Discovery and development of new eye therapeutics for diseases with unmet medical need.

Biotech in stealth mode
Developing a novel digital therapeutic for the treatment of migraine

CellSpring
CellSpring analyzes human cells grown in special 3-Dimensional environments to develop new tools for diagnosing early-stage cancer.

CMET Pharmaceuticals
CMET Pharmaceuticals aims to develop novel therapies for the treatment of metastatic cancers, tailored to target circulating tumour cell clusters.

Cureab
Cureab develops antibodies for cancer therapy focussing on lung, liver and colorectal cancer.

Epibloc
Epibloc applies a proprietary immunoprofiling platform to identify peptides that bind to specific autoantibodies involved in autoimmune diseases. The peptides are then used to develop companion diagnostics and precision drugs to eliminate only the disease causing autoantibodies.

logo Pattern BiosciencesPattern Biosciences
Next generation programmable therapies powered by Synthetic Biology.

Polyneuron Pharmaceuticals AG
Polyneuron is committed to the development of a promising new drug class to treat autoimmune disorders.

Logo-SiBreaxSiBreax
SiBreaX develops stimulus responsive silicate-based nano-/microparticles for targeted drug/compound delivery and degradable, injectable nanocomposite hydrogels for biomedical and topical applications. Leveraging its platform technology of nano-/microparticles and hydrogels, SiBreaX partners in development as well as develops own drugs and medical hydrogels.

SunRegen Healthcare AG
SunRegen develops novel drugs for neurodegenerative diseases.

SynEndoS Therapeutics
Developing a new medicine to treat anxiety and stress related disorders by modulating the activity of cannabinoid molecules already present in the human body.

T3 Pharmaceuticals AG
T3 Pharma develops the next generation bacterial cancer therapy.

TEPTHERA
The mission of TEPTHERA is to offer individualized therapeutic cancer vaccines.

TheraNASH
TheraNASH develops precision medicine for fatty liver disease – a rising cause of liver cancer world-wide.

Versameb
VERSAMEB is a regenerative medicine research and development company.

Biotech Office Buildings